Turning Point Therapeutics Inc. has the chance to secure a piece of the market for ROS1-positive non-small cell lung cancer with its ROS1/TRK inhibitor, repotrectinib, after presenting positive Phase I/II data that showed efficacy in line with competitors, but with longer durability.
The company announced topline data by blinded independent central review (BICR) from the TRIDENT-1 trial. The data showed confirmed overall...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

